Pegylated nanoliposomes remote-loaded with the antioxidant tempamine ameliorate experimental autoimmune encephalomyelitis

Journal of Neuroimmunology

Volumn 213, Issue 1-2, 2009, Pages 20-25

  Kizelsztein, Pablo ^a   Ovadia, Haim ^b   Garbuzenko, Olga ^a   Sigal, Alex ^a   Barenholz, Yechezkel ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Antioxidants; EAE; Liposomes; MS; Neurodegeneration; Tempamine

Indexed keywords

AMMONIUM SULFATE; ANTIOXIDANT; CHOLESTEROL ESTER; GAMMA INTERFERON; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; LIPOSOME; MACROGOL 2000; N,N,N TRIMETHYLTEMPAMINE; PHOSPHATIDYLETHANOLAMINE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; ENCAPSULATION; FEMALE; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ANIMALS; ANTIOXIDANTS; BLOOD-BRAIN BARRIER; BRAIN; CYCLIC N-OXIDES; DIFFUSION; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; LIPOSOMES; MICE; NANOCAPSULES; OXIDATIVE STRESS; POLYETHYLENE GLYCOLS; REACTIVE OXYGEN SPECIES; SULFONIC ACIDS; TREATMENT OUTCOME;

EID: 68049102034     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.05.019     Document Type: Article

References (35)

1. Afzal V., Brasch R.C., Nitecki D.E., and Wolff S. Nitroxyl spin label contrast enhancers for magnetic resonance imaging. Studies of acute toxicity and mutagenesis. Invest. Radiol. 19 (1984) 549-552
2. Avnir Y., Ulmansky R., Wasserman V., Even-Chen S., Broyer M., Barenholz Y., and Naparstek Y. Amphipathic weak acid glucocorticoid prodrugs remote-loaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a Beagle dog: a novel approach to treating autoimmune arthritis. Arthritis Rheum. 58 (2008) 119-129
3. Barenholz Y. In: Gregoriadis G. (Ed). Liposome Technology vol. I (1993), CRC Press, Boca Raton 527-616
4. Barenholz Y. Cholesterol and other membrane active sterols: from membrane evolution to "rafts". Prog. Lipid Res. 41 (2002) 1-5
5. Barenholz Y. Relevancy of drug loading to liposomal formulation therapeutic efficacy. J. Liposome. Res. 13 (2003) 1-8
6. Barenholz Y. Amphipathic weak base loading into preformed liposomes having a transmembrane ammonium ion gradient: from the bench to approved DOXIL. In: Gregoriadis G. (Ed). Liposome Technology vol. 26 (2007), CRC Press, Boca Raton 1-26
7. Borlongan C.V., Kanning K., Poulos S.G., Freeman T.B., Cahill D.W., and Sanberg P.R. Free radical damage and oxidative stress in Huntington's disease. J. Fla. Med. Assoc. 83 (1996) 335-341
8. Calabrese V., Guagliano E., Sapienza M., Panebianco M., Calafato S., Puleo E., Pennisi G., Mancuso C., Butterfield D.A., and Stella A.G. Redox regulation of cellular stress response in aging and neurodegenerative disorders: role of vitagenes. Neurochem. Res. 32 (2007) 757-773
9. Cavaletti G., Cassetti A., Canta A., Galbiati S., Gilardini A., Oggioni N., Rodriguez-Menendez V., Fasano A., Liuzzi G.M., Fattler U., Ries S., Nieland J., Riccio P., and Haas H. Cationic liposomes target sites of acute neuroinflammation in experimental autoimmune encephalomyelitis. Mol. Pharm. 6 4 (2009) 1050-1058
10. Clerc S., and Barenholz Y. Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients. Biochim. Biophys. Acta 1240 (1995) 257-265
11. DeGraff W.G., Krishna M.C., Kaufman D., and Mitchell J.B. Nitroxide-mediated protection against X-ray-and neocarzinostatin-induced DNA damage. Free Radic. Biol. Med. 13 (1992) 479-487
12. Ebadi M., Srinivasan S.K., and Baxi M.D. Oxidative stress and antioxidant therapy in Parkinson's disease. Prog. Neurobiol. 48 (1996) 1-19
13. Ferrante R.J., Browne S.E., Shinobu L.A., Bowling A.C., Baik M.J., MacGarvey U., Kowall N.W., Brown Jr. R.H., and Beal M.F. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J. Neurochem. 69 (1997) 2064-2074
14. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., Martin F., Huang A., and Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54 (1994) 987-992
15. Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18 (2001) 685-716
16. Haran G., Cohen R., Bar L.K., and Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta 1151 (1993) 201-215
17. Huitinga I., van Rooijen N., de Groot C.J., Uitdehaag B.M., and Dijkstra C.D. Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J. Exp. Med. 172 (1990) 1025-1033
18. Kedar E., Rutkowski Y., Braun E., Emanuel N., and Barenholz Y. Delivery of cytokines by liposomes. I. Preparation and characterization of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes. J. Immunother. Emphasis. Tumor Immunol. 16 (1994) 47-59
19. Krishna M.C., Grahame D.A., Samuni A., Mitchell J.B., and Russo A. Oxoammonium cation intermediate in the nitroxide-catalyzed dismutation of superoxide. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 5537-5541
20. Lu F., Selak M., O'Connor J., Croul S., Lorenzana C., Butunoi C., and Kalman B. Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. J. Neurol. Sci. 177 (2000) 95-103
21. Markesbery W.R., and Carney J.M. Oxidative alterations in Alzheimer's disease. Brain Pathol. 9 (1999) 133-146
22. Mitchell J.B., DeGraff W., Kaufman D., Krishna M.C., Samuni A., Finkelstein E., Ahn M.S., Hahn S.M., Gamson J., and Russo A. Inhibition of oxygen-dependent radiation-induced damage by the nitroxide superoxide dismutase mimic, tempol. Arch. Biochem. Biophys. 289 (1991) 62-70
23. Muldoon L.L., Soussain C., Jahnke K., Johanson C., Siegal T., Smith Q.R., Hall W.A., Hynynen K., Senter P.D., Peereboom D.M., and Neuwelt E.A. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J. Clin. Oncol. 25 (2007) 2295-2305
24. Muller D.M., Pender M.P., and Greer J.M. Blood-brain barrier disruption and lesion localisation in experimental autoimmune encephalomyelitis with predominant cerebellar and brainstem involvement. J. Neuroimmunol. 160 (2005) 162-169
25. Offen D., Kaye J.F., Bernard O., Merims D., Coire C.I., Panet H., Melamed E., and Ben-Nun A. Mice overexpressing Bcl-2 in their neurons are resistant to myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE). J. Mol. Neurosci. 15 (2000) 167-176
26. Peleg-Shulman T., Gibson D., Cohen R., Abra R., and Barenholz Y. Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance. Biochim. Biophys. Acta 1510 (2001) 278-291
27. Pollak Y., Ovadia H., Orion E., Weidenfeld J., and Yirmiya R. The EAE-associated behavioral syndrome: I. Temporal correlation with inflammatory mediators. J. Neuroimmunol. 137 (2003) 94-99
28. Samuni A., Mitchell J.B., DeGraff W., Krishna C.M., Samuni U., and Russo A. Nitroxide SOD-mimics: modes of action. Free Radic. Res. Commun. 12-13 Pt 1 (1991) 187-194
29. Sarsero J.P., Li L., Wardan H., Sitte K., Williamson R., and Ioannou P.A. Upregulation of expression from the FRDA genomic locus for the therapy of Friedreich ataxia. J. Genet. Med. 5 (2003) 72-81
30. Schmidt J., Metselaar J.M., Wauben M.H., Toyka K.V., Storm G., and Gold R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 126 (2003) 1895-1904
31. Shmeeda H., Even-Chen S., Honen R., Cohen R., Weintraub C., and Barenholz Y. Enzymatic assays for quality control and pharmacokinetics of liposome formulations: comparison with nonenzymatic conventional methodologies. Methods Enzymol. 367 (2003) 272-292
32. Strejan G.H., and St Louis J. Suppression of experimental allergic encephalomyelitis by MBP-coupled lymphoid cells and by MBP-liposomes: a comparison. Cell. Immunol. 127 (1990) 284-298
33. Tonra J.R., Reiseter B.S., Kolbeck R., Nagashima K., Robertson R., Keyt B., and Lindsay R.M. Comparison of the timing of acute blood-brain barrier breakdown to rabbit immunoglobulin G in the cerebellum and spinal cord of mice with experimental autoimmune encephalomyelitis. J. Comp. Neurol. 430 (2001) 131-144
34. Wasserman V., Kizelsztein P., Garbuzenko O., Kohen R., Ovadia H., Tabakman R., and Barenholz Y. The antioxidant tempamine: in vitro antitumor and neuroprotective effects and optimization of liposomal encapsulation and release. Langmuir 23 (2007) 1937-1947
35. Willenborg D.O., and Higgins T.J. Liposomes containing myelin basic protein (BP) suppress but do not induce allergic encephalomyelitis in Lewis rats. Aust. J. Exp. Biol. Med. Sci. 59 (1981) 135-141